Adding to its growing rare disease pipeline, Pfizer has agreed to acquire Therachon for a total deal value of US$810 M. Pfizer gains Therachon’s rare musculoskeletal franchise which includes TA-46 and TA-100 for the treatment of achondroplasia and other skeletal dysplasias. Therachon’s other experimental asset, apraglutide, will be spun-off into a separate and independent company prior to the closing of the Pfizer deal.